Please assess the completion status of the following clinical trial:

Trial Title: Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a confirmed diagnosis of non-M3 AML; antecedent myelodysplastic syndrome (MDS) is acceptable~* Post autologous stem cell transplant bone marrow biopsy core that is consistent with morphologic remission~* Must have received induction and consolidation chemotherapy, and autologous stem cell transplant for AML~* Life expectancy of greater than 12 months~* Karnofsky performance status 70 or greater~* Leukocytes \>= 2,000/mcL~* Absolute neutrophil count \>= 1,000/mcL~* Platelets \>= 75,000/mcL~* Total bilirubin =\< 4 X institutional upper limit of normal unless 2nd to Gilbert's disease~* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 4 X institutional upper limit of normal~* Creatinine \< 1.5 X institutional upper limit of normal OR creatinine clearance \>= 30 mL/min/1.73 m\^2 for patients with creatinine levels above institutional normal~* Able to take aspirin, or warfarin, or low molecular weight heparin as prophylactic anticoagulation~* Ability to understand and the willingness to sign a written informed consent document~* Must be registered into the mandatory RevAssist® program and be willing and able to comply with the requirement of RevAssist®~Exclusion Criteria:~* Patient received chemotherapy or radiotherapy within 2 weeks prior to entering the study or has not recovered from adverse events due to agents administered more than 4 weeks earlier~* Patient received another investigational agent after post autologous stem cell transplant~* Patient who will be receiving another investigational product during the study~* Patient who is growth factor or transfusion dependent~* Patient has central nervous system leukemia~* History of allergic reactions attributed to thalidomide or lenalidomide~* History of erythema nodosum, characterized by a desquamating rash while taking thalidomide or similar drugs~* Prior history of metastatic malignancy~* Uncontrolled illness including, but not limited to ongoing or active infection, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements; patients must not have suffered recent (\< 6 months) myocardial infarction, unstable angina, uncontrolled hypertension, or difficult to control cardiac arrhythmias~* Evidence of uncontrolled congestive heart failure~* Active hepatitis B as defined by hepatitis B surface antigen positivity, unless able to start dual anti-hepatitis B (HepB) therapy, or already on dual anti-HepB therapy~* Patients who are positive for hepatitis B core antibody, but negative for the hepatitis B surface antigen, should be on lamivudine 100 mg daily until at least 3 months post-transplant~* Patient is positive for human immunodeficiency virus (HIV) or human T-cell lymphotropic virus-1 (HTLV-1)~* Women of childbearing potential (defined as a sexually mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 consecutive months)~* Men who did not agree not to father a child and who refused to use a latex condom during any sexual contact with women of childbearing potential while taking lenalidomide and for 4 weeks after therapy is stopped, even if they have undergone a successful vasectomy

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (lenalidomide) (Type: EXPERIMENTAL): Patients receive lenalidomide PO QD on days 1-21. Courses repeat 4 weeks in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).